- Home
- TPIC vs GUTS Comparison
TPIC vs GUTS Comparison
Compare TPIC & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- GUTS
- Stock Information
- Founded
- TPIC 1968
- GUTS 2010
- Country
- TPIC United States
- GUTS United States
- Employees
- TPIC N/A
- GUTS N/A
- Industry
- TPIC Industrial Machinery/Components
- GUTS
- Sector
- TPIC Industrials
- GUTS
- Exchange
- TPIC Nasdaq
- GUTS NYSE
- Market Cap
- TPIC 65.6M
- GUTS 54.8M
- IPO Year
- TPIC 2016
- GUTS 2024
- Fundamental
- Price
- TPIC $0.73
- GUTS $1.22
- Analyst Decision
- TPIC Hold
- GUTS Buy
- Analyst Count
- TPIC 6
- GUTS 1
- Target Price
- TPIC $1.86
- GUTS $10.00
- AVG Volume (30 Days)
- TPIC 684.9K
- GUTS 272.1K
- Earning Date
- TPIC 05-08-2025
- GUTS 05-12-2025
- Dividend Yield
- TPIC N/A
- GUTS N/A
- EPS Growth
- TPIC N/A
- GUTS N/A
- EPS
- TPIC N/A
- GUTS N/A
- Revenue
- TPIC $1,331,131,000.00
- GUTS $93,000.00
- Revenue This Year
- TPIC $8.93
- GUTS N/A
- Revenue Next Year
- TPIC $9.59
- GUTS N/A
- P/E Ratio
- TPIC N/A
- GUTS N/A
- Revenue Growth
- TPIC N/A
- GUTS N/A
- 52 Week Low
- TPIC $0.64
- GUTS $0.87
- 52 Week High
- TPIC $5.75
- GUTS $7.89
- Technical
- Relative Strength Index (RSI)
- TPIC 40.56
- GUTS 52.03
- Support Level
- TPIC $0.73
- GUTS $0.87
- Resistance Level
- TPIC $0.92
- GUTS $1.17
- Average True Range (ATR)
- TPIC 0.09
- GUTS 0.11
- MACD
- TPIC 0.01
- GUTS 0.02
- Stochastic Oscillator
- TPIC 31.10
- GUTS 87.41
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.